Fibroblast growth factor 23
Edward R Smith, Lawrence P McMahon, Stephen G Holt
ANNALS OF CLINICAL BIOCHEMISTRY | SAGE PUBLICATIONS INC | Published : 2014
There is growing interest in the role of fibroblast growth factor 23 (FGF23) in various diseases of disordered mineral metabolism. In chronic kidney disease (CKD), where biochemical evidence of mineral disturbances is especially common, FGF23 measurement has been advocated as an early and sensitive marker for CKD-related bone disease. In this setting, FGF23 analysis may also improve the discrimination of risk of adverse renal and cardiovascular outcomes and aid targeting of those patients that are likely to benefit from interventions. Nonetheless, while the physiological relevance of FGF23 in the control of mineral metabolism is now firmly established, relatively little attention has been pa..View full abstract
ERS, LPM and SGH have received research funding from Amgen and Baxter. ERS has received honoraria from Shire; LPM has received honoraria from Amgen and Roche; SGH has received honoraria from Amgen, Baxter, Gilead and Shire.